

Table 1d. Antibody Performance, Weeks 1 and 2 – Total Antibodies

Total Antibodies	Week 1			Week 2		
Sensitivity	0.50 (95% CI: 0.32 to 0.69)			0.94 (95% CI: 0.84 to 0.98)		
Specificity	1.00 (95% CI: 0.99 to 1.00)					
Outcome	Effect per 1,000 patients tested					
	pre-test probability of 1% ^a	pre-test probability of 10% ^b	pre-test probability of 40% ^c	pre-test probability of 1% ^a	pre-test probability of 10% ^b	pre-test probability of 40% ^c
True positives (patients with COVID-19)	5 (3 to 7)	50 (32 to 69)	200 (128 to 276)	9 (8 to 10)	94 (84 to 98)	376 (336 to 392)
False negatives (patients incorrectly classified as not having COVID-19)	5 (3 to 7)	50 (31 to 68)	200 (124 to 272)	1 (0 to 2)	6 (2 to 16)	24 (8 to 64)
Quality of the evidence	7 studies, 418 patients ⊕○○○ VERY LOW ^{d,e,f}			6 studies, 359 patients ⊕⊕○○ LOW ^{d,e}		
	pre-test probability of 1% ^a		pre-test probability of 10% ^b		pre-test probability of 40% ^c	
True negatives (patients without COVID-19)	990 (980 to 990)		900 (891 to 900)		600 (594 to 600)	
False positives (patients incorrectly classified as having COVID-19)	0 (0 to 10)		0 (0 to 9)		0 (0 to 6)	
Quality of Evidence	8 studies, 4521 patients ⊕⊕⊕○ MODERATE ^d					

a. Typically seen in general population in areas that are not hotspots

b. Typically seen in general population in high risk populations

c. Typically seen in general population in exposed and nursing homes

d. The case-control design leads to a serious risk of bias

e. Unexplained inconsistency observed with considerably variable sensitivity. Sensitivity Ranges: C1: 0.03-0.75, C2: 0.74-1.00

f. Considering the Upper vs Lower limits of the sensitivity's confidence interval would lead to different clinical decisions.